Evidence map›Paper›PMID 41301730›Full record

ReviewBiomedicines2025

A Narrative Review of Evidence, Safety, and Clinical Considerations in Taxane Chemotherapy for Pregnancy-Associated Breast Cancer.

Jenny W Zhang, Ochuwa Precious Imokhai, Danny Lee, Diana Hamdan, Trisha Mahajan, Satyam K Singh, Amanda Brooks

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jenny W ZhangMontana College of Osteopathic Medicine, Rocky Vista University, Billings, MT 59106, USA.ORCID 0000-0002-3709-4798
Ochuwa Precious ImokhaiMontana College of Osteopathic Medicine, Rocky Vista University, Billings, MT 59106, USA.ORCID 0009-0008-1015-7526
Danny LeeDepartment of Medicine, University of California, San Francisco St. Mary's Hospital, San Francisco, CA 94117, USA.
Diana HamdanCollege of Osteopathic Medicine, Kansas City University, Joplin, MO 64804, USA.ORCID 0000-0001-9625-378X
Trisha MahajanDepartment of Medicine, Texas College of Osteopathic Medicine, Fort Worth, TX 76107, USA.
Satyam K SinghCollege of Medicine, University of Illinois, Chicago, IL 60612, USA.ORCID 0009-0001-5449-8882
Amanda BrooksDepartment of Research in Scholarly Activity, College of Osteopathic Medicine, Rocky Vista University, Ivins, UT 84738, USA.ORCID 0000-0001-9785-5969

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The medical condition of pregnancy-associated breast cancer (PABC) requires oncologists to determine the best way to protect both the mother and the fetus during cancer treatment. The safety profile of taxanes, including paclitaxel and docetaxel, in the second and third trimesters of pregnancy remains unclear despite well-established anthracycline-based regimens (e.g., doxorubicin). High-risk breast cancer subtypes such as triple negative breast cancer (TNBC) and human epidermal growth factor receptor (HER2)-positive disease require taxane chemotherapy as standard treatment in nonpregnant patients.

Indexed as

chemotherapyfetal outcomesmaternal safetypregnancy-associated breast cancer (PABC)taxanes

Identifiers

PMID41301730
PMCPMC12650452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.